Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives $11.25 Consensus Price Target from Brokerages

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) have earned an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year […]

Related Keywords

,Morgan Stanley ,Fusion Pharmaceuticals Inc ,Fusion Pharmaceuticals Trading ,Sofinnova Investments Inc ,Tekla Capital Management ,Analyst Recommendations For Fusion Pharmaceuticals ,Nasdaq ,News Ratings For Fusion Pharmaceuticals Daily ,Fusion Pharmaceuticals ,Hermes Inc ,Get Rating ,Capital Management ,Sofinnova Investments ,Pharmaceuticals Inc ,Targeted Alpha Therapies ,Fusion Pharmaceuticals Daily ,Nasdaq Fusn ,Fusn ,Medical ,Ratings ,Consensus ,